Share
 ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌

Hi ,


In this episode of the SynBioBeta podcast, I chat with Michael Kamdar, President & CEO and Phil Paik, CTO, both of whom are at Molecular Assemblies—a San Diego-based life sciences company developing an enzymatic DNA synthesis technology designed to power the next generation of DNA-based products. We talked about the competitive DNA synthesis landscape, Molecular Assemblies plans for commercialization, and what Mike and Phil envision for the future of the company and the industry.

  • These 10 Women Investors Are Betting Big On Synthetic Biology Future. Eric Schmidt is not the only one who believes in the synthetic biology future. These ten investors – some of whom will be at the SynBioBeta conference next week – recognize the power of synthetic biology to solve many of today’s challenges and create new industries and markets with multi-billion-dollar potential.

Ansa Biotechnologies’ CEO Daniel Lin-Arlow.

What's new at SynBioBeta 2023:

SynBioBeta 2023: The Global Synthetic Biology Conference is just one week away! We look forward to bringing together experts from around the world to discuss the latest advancements and innovations in synthetic biology. 

Register now

The Industrial Microbes team aims to accelerate the transition to sustainable materials. After eight years of research and 20 patents, they have developed a biomanufacturing process that turns greenhouse gases (GHGs), starting with methane, into net-zero materials using gas-eating microorganisms. In addition, they have partnered with several chemical manufacturers to decarbonize production without cutting profits. Check out their white paper on the ROI of waste, or contact them for partnerships.

Other news:

  • Cradle, the platform that helps scientists to design and program proteins, today published the findings of its first BioDeveloper survey, exploring the methods and priorities of biodevelopers to build a picture of trends within the synthetic biology sector.

  • A-Alpha Bio and Lawrence Livermore National Laboratory expand collaboration to accelerate antibody discovery and development for biothreats. $2.4M in Department of Defense (DOD) funding to A-Alpha Bio will be used to generate large-scale antibody-antigen binding data for training computational models that accelerate drug discovery against possible biological threats.

  • Form Bio announces FORMsightAI, a breakthrough AI solution set for predicting and optimizing cell & gene therapy manufacturability. Form Bio FORMsightAI is a new, AI-based solution set for predicting and optimizing manufacturing outputs of cell and gene therapy constructs. Form Bio FORMsightAI is generally available to cell and gene therapy companies as well as CDMOs.

  • NewLimit secures $40 million in venture funding to extend human healthspan.

  • New method uses engineered bacteria and AI to sense and record environmental signals. Columbia synthetic biologists are the first to engineer bacterial swarm patterns to visibly record the environment, and use deep learning to decode patterns. Applications could range from monitoring environmental pollution to building living materials.

If you’ll be at SynBioBeta this month, I can’t wait to see you.


Regards,
John

---

John Cumbers
Founder, SynBioBeta

Who's hiring?

View in Browser »

Like our Digest? Please feel free to share with friends, family, and co-workers!


SynBioBeta, LLC
3559 Mount Diablo Boulevard #2, Lafayette, CA 94549

info@synbiobeta.com

If you no longer wish to receive our emails, you can unsubscribe here.
Modify Your Email Preferences


Email Marketing by ActiveCampaign